New scan may predict who will beat Triple-Negative breast cancer

NCT ID NCT06349512

Recruiting now Diagnosis Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a new type of PET scan (68Ga-FAPI-46) can predict if triple-negative breast cancer will completely respond to chemotherapy plus immunotherapy before treatment begins. About 60 women with early-stage, high-risk breast cancer will get the scan before starting standard treatment. The goal is to see if the scan can accurately tell doctors which patients will have no cancer left after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

GH Diaconesses Croix Saint-Simon
RECRUITING

Paris, 75020, France
HIA Begin
RECRUITING

Saint-Mandé, 94160, France
Hôpital FOCH
RECRUITING

Suresnes, 92150, France
Hôpital Privé d'Antony
RECRUITING

Antony, 92160, France
Institut Curie -site Paris
RECRUITING

Paris, 75005, France
Institut Curie -site St Cloud
RECRUITING

Saint-Cloud, 92210, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.